1 not yet recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Standard Third-Line Therapy: new trials by email Literature Review of Standard Third-Line Therapy trials Research Report on Standard Third-Line Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy. QL1706 + Fruquintinib + Short-Course Ablative Radiotherapy (SCART), Standard Third-Line Therapy - Colorectal Cancer | Phase 2 | Not yet recruiting | Tao Zhang | 76 | 2026-01-21 | 2026-01-20 |
Tao Zhang (1)
China (1)
Tao Zhang, MD (1)